Special Issue

Precision Medicine in Anesthesia and Pain

Message from the Guest Editor

Chronic pain impacts millions globally, leading to a significant decline in quality of life and placing a heavy burden on healthcare systems. Current treatment options often fail to provide sufficient relief without adverse effects, underscoring the critical need for new therapeutic targets. Additionally, the research topic will explore the potential of targeting NPY receptors as a novel therapeutic approach for pain management. By modulating NPY pathways, there is the possibility to develop innovative treatments that offer effective pain relief while reducing the risks of addiction and tolerance often associated with opioids. Preclinical and clinical research will be evaluated to determine the feasibility of NPY-based therapies and to identify potential challenges in transitioning these findings into clinical use. We call for original research articles and reviews on behavioral pharmacology, calcium imaging (in vitro and in vivo fiber photometry), electrophysiology, chemogenetics, optogenetics, viral tracing, etc.

Guest Editor

Dr. Paramita Basu

Pittsburgh Center for Pain Research, The Pittsburgh Project to End Opioid Misuse, Department of Anesthesiology & Perioperative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Deadline for manuscript submissions

30 May 2025

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/215784

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).